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St. John’s wort is 
safer than older 
antidepressants, 
but hasn’t 
been compared 
extensively with 
newer drugs, 
such as SSRIs.
	 Which	nutritional	therapies	
are	safe	and	effective		
for	depression?
i -  
	 st.	 john’s	 wort	 is	 effective	 for
	 short-term	 relief	 of	 mild	 to	moder-
ate	depression	(strength	of	recommendation	
[SOR]:	A;	1	systematic	review).	Its	safety	pro-
file	is	superior	to	older	antidepressants;	data	
comparing	 it	 with	 newer	 antidepressants	
(such	as	selective	serotonin	reuptake	inhibi-
tors)	are	limited	(SOR:	A,	1	systematic	review).
A	 small	 but	 statistically	 significant	
clinical	 benefit	has	 been	demonstrated	 for	
saffron,	 lavender,	 borage,	 dan	 zhi	 xiao	 yao	
(SOR:	B,	1	systematic	review	and	3	random-
ized	controlled	trials),	folate	(SOR:	A,	1	sys-
tematic	review),	and	S-adenosylmethionine	
(SAMe)	(SOR:	A,	1	meta-analysis	and	1	sys-
tematic	review).	Most	trials	of	these	prepa-
rations	 were	 short	 and	 small,	 limiting	 the	
ability	to	detect	adverse	effects.	
Tryptophan	 (SOR:	A,	 1	 systematic	 re-
view)	 and	 5-hydroxytryptophan	 (5-HTP)	
(SOR:	A,	1	systematic	review)	have	demon-
strated	superiority	over	placebo	in	alleviat-
ing	symptoms	of	depression,	but	concerns	
exist	about	their	safety.	
N-3	long-chain	polyunsaturated	fatty	ac-
ids	(n-3	PUFAs)	and	omega-3	fatty	acids	don’t	
appear	 effective	 in	 treating	 major	 depres-
sive	 disorder	 (SOR:	A,	 1	 systematic	 review.)
Evidence summary
TABLE W1	 (see	 page	 100a)	 summarizes	 study	
results	 and	 recommendations	 for	 nutritional	
therapies	for	depression.1-16
St. John’s wort works as well as  
standard antidepressants
A	recent	Cochrane	review	suggested	that	St.	
John’s	wort	is	more	effective	than	placebo	in	
patients	 with	 mild	 to	 moderate	 depression	
and	as	effective	as	standard	antidepressants.1	
Other supplements also have benefits 
A	 systematic	 review	 of	 4	 small	 randomized	
controlled	trials	(RCTs)	suggested	that	saffron	
(30	 mg)	 is	 superior	 to	 placebo	 in	 treating	
short-term	depression	 (6	weeks).	Treatment	
and	outcomes	were	equivalent	 to	fluoxetine	
and	imipramine.2	A	later	RCT	yielded	results	
consistent	with	the	systematic	review.3	
Combined	 lavender tincture	 (60	 drops	
per	day)	and	imipramine	were	more	effective	
than	imipramine	alone	in	1	small	RCT.4	
Borage,	 a	 traditional	 Persian	medicine,	
was	superior	 to	placebo	in	reducing	depres-
sive	symptoms	in	1	small	RCT.2	
Dan zhi xiao yao,	 a	 traditional	 Chinese	
medicine,	was	as	effective	as	the	tricyclic	anti-
depressant	maprotiline	in	1	small	RCT.2	
Three	RCTs	suggested	that	folate	may	be	
used	 to	 supplement	 conventional	 treatments	
for	 depression,	 but	 it	 isn’t	 clear	whether	 this	
would	help	patients	with	normal	folate	levels.5	
A	 meta-analysis	 of	 13	 controlled	 clinical	
trials	and	a	later	systematic	review	of	11	articles	
including	2	RCTs	concluded	that	SAMe	is	more	
effective	 than	 placebo	 and	 as	 efficacious	 as	
tricyclic	 antidepressants	 in	 treating	major	de-
pression	 in	 adults.	However,	 further	 trials	 are	
needed	to	answer	questions	about	absorption,	
mechanism	of	action,	and	bioavailability.6,7
Tryptophan’s benefit comes with risk 
In	 a	 Cochrane	 review	 of	 2	 RCTs,	 tryptophan	
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and	 5-HTP	 were	 superior	 to	 placebo	 in	 al-
leviating	 symptoms	 of	 depression.	 How-
ever,	 some	 published	 case	 reports	 have	
linked	 tryptophan	 use	 to	 potentially	 fatal	
eosinophilia-myalgia	syndrome.8	
No clear evidence for inositol  
or n-3 PUFAs
A	 Cochrane	 review	 of	 4	 small	 double-blind	
RCTs	 investigating	 inositol	 as	 a	 nutritional	
supplement	in	depression	treatment	failed	to	
find	clear	evidence	of	therapeutic	benefit.9	
Three	 RCTs	 demonstrated	 significantly	
higher	red	blood	cell	membrane	levels	of	n-3	
PUFAs	 in	 nondepressed	 patients	 compared	
with	depressed	patients.10	However,	a	system-
atic	 review	 of	 12	 RCTs	 failed	 to	 demonstrate	
any	benefit	of	n-3	PUFA	supplementation	over	
placebo	in	treating	depressed	mood.11	The	au-
thors	concluded	that	larger	trials	are	needed	to	
demonstrate	efficacy	because	of	marked	het-
erogeneity	among	the	RCTs.
z Safety issues. A	recent	Cochrane	review	
found	fewer	adverse	effects	for	St.	John’s	wort	
than	tricyclic	antidepressants.1	The	most	com-
mon	adverse	reactions	were	sensitivity	to	light,	
skin	 symptoms,	 gastrointestinal	 symptoms,	
and	agitation.	Data	comparing	St.	John’s	wort	
with	newer	antidepressants	are	lacking.	
St.	 John’s	 wort	 does	 have	 pharmacoki-
netic	 interactions	 and	 should	 not	 be	 taken	
concurrently	 with	 other	 antidepressants,	
immunosuppressants,	 anti-HIV	 drugs,	 cou-
marin-type	anticoagulants,	or	certain	antineo-
plastic	agents.17	
Reviews	 of	 meta-analyses,	 case	 reports,	
population	studies,	RCTs,	and	other	literature	
have	 reported	virtually	no	adverse	effects	 for	
PUFAs;18	 trials	 investigating	 saffron,	 laven-
der,	 borage,	 dan	 zhi	 xiao	 yao,	 folate,	 SAMe,	
and	inositol	also	reported	no	safety	concerns.	
However,	the	size	and	duration	of	these	stud-
ies	limit	their	ability	to	detect	significant	prob-
lems.2,5,6,9	As	previously	noted,	 concerns	exist	
regarding	an	association	between	tryptophan	
and	eosinophilia-myalgia	syndrome.8	
Recommendations
The	World	Federation	of	Societies	of	Biological	
Psychiatry	doesn’t	recommend	St.	 John’s	wort	
for	moderate	to	severe	depression,	but	suggests	
it	can	be	considered	for	treating	mild	to	moder-
ate	depressive	episodes	provided	the	prescriber	
considers	 potential	 pharmacokinetic	 interac-
tions	with	other	medications	and	understands	
possible	variations	in	purity	and	potency	of	ex-
tracts.19	The	Federation	also	states	that	St.	John’s	
wort	 is	 an	 alternative	 for	 patients	 reluctant	 to	
take	traditional	antidepressants.	 														JFP
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TABLE W1
What	the	studies	say	about	nutritional	therapies	for	depression
 
Supplement
 
Study type
Number of 
subjects
 
comparison group
outcome  
measure
 
results
 
conclusion
 
Sor
borage 
(Echium 
amoenum)
1 small rcT 352,16 Placebo ham-D Improved ham-D 
scores significantly 
at week 4 (borage 
18.3 ± 3.9 vs 
placebo 21.9 ± 
3.9; t=2.51; P=.02); 
no significant 
difference at  
Week 62,16
Superior to 
placebo in 
reducing 
symptoms of 
depression
b
Dan zhi xiao 
yao
1 small rcT 632 maprotiline ham-D, SDS, 
SaS, scale for 
traditional 
chinese 
medicine 
syndrome 
and symptom 
differentiation
87% depression 
reduction (dan 
zhi xiao yao) vs 
84% depression 
reduction 
(maprotiline) 
as effective as 
maprotiline 
in treating 
depression
b
Folate cochrane 
review of  
3 rcTs
2475 Studies 1 and 2: 
folate vs folate + 
other treatment 
(Study 1: low folate 
levels; Study 2: 
normal folate levels) 
Study 3: folate vs 
trazodone (normal 
folate levels)
ham-D Superior to placebo 
(NNT=5, defined 
as 50% reduction 
in ham-D); 
comparable 
to trazodone 
(rr=0.97; 95% cI, 
0.14-2.01)7
may have role as 
supplement to 
other treatments 
for depression 
Efficacy unclear 
in patients with 
normal folate 
levels
a
Inositol cochrane 
review of  
4 rcTs
1419 Studies 1-3: placebo 
plus conventional 
antidepressants 
Study 4: placebo 
only
ham-D, 
maDrS
Pooled estimate 
of effect of all 
3 studies (SmD= 
−0.08; 95% cI,  
−0.45 to 0.30)
No clear 
evidence of 
therapeutic 
benefit 
a
lavender 
(Lavandula 
angustifolia)
1 small rcT 454 Imipramine ham-D Imipramine plus 
lavender showed 
significant effect 
compared with 
imipramine alone 
(F=26.87; DF=3.01; 
P<.0001)
Synergistic 
effect suggested 
when used with 
imipramine
b
bDI, beck Depression Inventory; cI, confidence interval; DF, degrees of freedom; ES, effect size; F, F statistic; ham-D, hamilton Depression rating Scale; maDrS, mont-
gomery-asberg Depression rating Scale; muFas, monounsaturated fatty acids; n-3 PuFas, n-3 long-chain polyunsaturated fatty acids; NNT, number needed to treat; 
or, odds ratio; PuFas, polyunsaturated fatty acids; rbc, red blood cell; rcT, randomized controlled trial; rr, relative risk; SaS, self-rating anxiety scale; SDS, self-rating 
depression scale; SFas, saturated fatty acids; SmD, standard weighted mean difference; Sor, strength of recommendation; SSrI, selective serotonin reuptake inhibitor.
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TABLE W1
What	the	studies	say	about	nutritional	therapies	for	depression	continued
 
Supplement
 
Study type
Number of 
subjects
 
comparison group
outcome 
measure
 
results
 
conclusion
 
Sor
n-3 long-
chain poly-
unsaturated 
fatty acids
Systematic 
review 
including  
3 rcTs;10
meta-
analysis of 
12 rcTs11
10210
103211
Various comparison 
groups included
Serum SFas, 
muFas, 
PuFas; rbc 
membrane 
levels n-3 
PuFas2
ham-D, bDI3
Systematic review:10 
Study 1: n=30; ES=3.61
Study 2: n=24; ES=1.2 
Study 3: n=48; ES=2.43
meta-analysis:11
Pooled ES=0.13;  
95% cI, 0.01-0.25
Significantly higher 
rbc membrane 
levels of n-3 PuFas 
in nondepressed vs 
depressed patients10
No significant 
effect for 
supplementation11
larger trials with 
adequate power 
needed2,3
a
S-adenosyl-
methionine 
(Same)
meta-
analysis of 
13 rcTs,6 
systematic 
review 
including  
2 rcTs7
3996
787
Placebo and 
conventional 
antidepressants
ham-D NNT=2.5 for ham-D 
decrease of ≥25%;6
NNT=6.25 for ham-D 
decrease of ≥50%6
may have role in 
treatment of major 
depression 
Further trials are 
needed to address 
unanswered 
questions about 
absorption, 
mechanism of 
action, and 
bioavailability7
a
Saffron 
(Crocus 
sativus)
Systematic 
review of  
4 small rcTs, 
1 later rcT
3012
4013
4014
4015
403
Imipramine12 
Placebo13,15 
Fluoxetine5,14
ham-D Systematic review: 
Study 1: imipramine 
and saffron equally 
efficacious (F=2.91; 
P=.09)12
Study 2: Improved 
ham-D scores: −12.20 
± 4.67 (saffron) vs 
−5.10 ± 4.71 (placebo) 
(P<.0001)13
Study 3: Improved 
ham-D scores: saffron 
petal −12.00 ± 4.10; 
fluoxetine −13.50 
± 4.91; difference 
between 2 treatments 
not significant 
(P=.27)14
Study 4: Improved 
ham-D scores: −14.01 
± 5.53 (saffron petal) 
vs −5.05 ± 4.63 
(placebo) (P<.0001)15
Study 5:5 NNT=10
Efficacy of 
extract and petal 
suggested to treat 
mild to moderate 
depression
large-scale trials 
are warranted
b
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TABLE W1
What	the	studies	say	about	nutritional	therapies	for	depression	continued
 
Supplement
 
Study type
Number of 
subjects
 
comparison group
outcome 
measure
 
results
 
conclusion
 
Sor
St. john’s 
wort 
(Hypericum 
perforatum 
L.)
cochrane 
review of  
29 rcTs
54891 SSrIs, tri/tetracyclic 
antidepressants,  
placebo
responder 
rate ratio
St. john’s wort vs 
placebo:  
   9 larger trials: 
rr=1.28; 95% cI, 1.10-
1.491 
   9 smaller trials: 
rr=1.87; 95% cI, 1.22-
2.871
St. john’s wort vs 
SSrIs: 12 trials: 
rr=1.00;  
95% cI, 0.90-1.111
St. john’s wort vs 
tricyclics: 5 trials: 
rr=1.02; 
95% cI, 0.90-1.151
Effective for 
treating mild 
to moderate 
depression
a
Tryptophan  
and  
5-hydroxy-
tryptophan 
(5-hTP)
cochrane 
review of  
2 rcTs
648 Placebo ham-D NNT=2.78 vs placebo 
(or=4.1;  
95% cI, 1.28-13.15
Superior to 
placebo 
Insufficient 
evidence 
regarding safety
a
